Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Solifenacin Succinate,Tamsulosin
Therapeutic Area : Urology
Study Phase : Approved FDF
Recipient : Adalvo
Deal Size : Inapplicable
Deal Type : Inapplicable
Adalvo and Adamed Pharma Team up to Launch Solifenacin + Tamsulosin in Europe
Details : Solifenacin Succinate is a muscarinic receptor antagonist and tamsulosin is an alpha-1A and alpha-1B adrenergic receptor antagonist used in combination to treat benign prostatic hyperplasia.
Product Name : Vesomni-Generic
Product Type : Miscellaneous
Upfront Cash : Inapplicable
May 23, 2023
Lead Product(s) : Solifenacin Succinate,Tamsulosin
Therapeutic Area : Urology
Highest Development Status : Approved FDF
Recipient : Adalvo
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Lactobacillus Rhamnosus ATCC 53103
Therapeutic Area : Gastroenterology
Study Phase : Undisclosed
Recipient : Medical University of Warsaw
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Lactobacillus Rhamnosus ATCC 53103 is a drug candidate, which is currently being evaluated in clinical studies for the treatment of Diarrhea.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
February 20, 2020
Lead Product(s) : Lactobacillus Rhamnosus ATCC 53103
Therapeutic Area : Gastroenterology
Highest Development Status : Undisclosed
Recipient : Medical University of Warsaw
Deal Size : Inapplicable
Deal Type : Inapplicable
Reset All
